EUVIMEDEUVIMED entdecken
Crossref

Study on the pharmacokinetics of 2-fluorodeschloroketamine and its metabolite in rats

Zhe Chen, Ye Liu, Huan Gao, Di Liang, Zhuoyi Wang, Chao Zhang, Jianguo Li, Zhiwen Wei, Dan Zhang, Keming Yun

Forensic Sciences Research · 2026 · 11 (1) · tfsr20240235

DOI: 10.3788/tfsr20240235 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Forensic Sciences Research, 2026. Verfasst von Zhe Chen und 9 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Currently, 2-fluorodeschloroketamine (2F-DCK), an analog of ketamine (KET), is considered one of the emerging new psychoactive substances (NPS). Its abuse is on the rise globally due to its structural and anesthetic similarities to KET. The pharmacological properties of KET have been extensively studied, but reports on the pharmacology of 2F-DCK and its metabolites are scarce. In the study, we focused on the pharmacokinetics of 2F-DCK and its phase I metabolite nor-2F-DCK in rodent model. Our aim was to analyse changes in their metabolic profiles over time and to construct a predictive model based on the concentration ratio of 2F-DCK to its metabolite for estimating the last 2F-DCK administration time. Eighteen healthy Sprague-Dawley (SD) male rats were randomly divided into three groups: high-and low-dose 2F-DCK groups and a control group ( n = 6). Whole blood was collected from the inner canthal vein at different time intervals after oral gavage. The blood samples were extracted via liquid-liquid extraction and analysed by high-performance liquid chromatography−tandem mass spectrometry (HPLC-MS/MS) in a positive ion mode using multi-reaction monitoring. Mean blood concentration−time curves showed that 2F-DCK was undetectable at 8 h post-administration, whereas nor-2F-DCK was still detectable at 12 h (low-dose group), demonstrating that nor-2F-DCK could be used as a reliable biomarker for 2F-DCK identification. Pharmacokinetic parameters were calculated by a pharmacokinetic software DAS 3.2.8, employing a non-compartment model. The results showed the elimination half-lives of 2F-DCK are 0.20 h (low-dose group) and 1.07 h (high-dose group); while those of nor-2F-DCK were 1.51 h (low-dose group) and 5.01 h (high-dose group), respectively. The time of maximum concentration ( T max ) of 2F-DCK in low-dose group was same as that in high-dose group (0.25 h), and the T max of nor-2F-DCK in both groups was 1.00 h, which indicated that the T max was dose-independent. Significantly, the best predictive model was obtained from the relationship between the concentration ratio of 2F-DCK to nor-2F-DCK and the administration time of 2F-DCK, exhibiting considerable potential for application in clinical drug monitoring and forensic illegal drug identification.

Zitieren

APA

Chen, Z., Liu, Y., Gao, H., Liang, D., Wang, Z., Zhang, C., Li, J., Wei, Z., Zhang, D., & Yun, K. (2026). Study on the pharmacokinetics of 2-fluorodeschloroketamine and its metabolite in rats. Forensic Sciences Research, 11(1), tfsr20240235. https://doi.org/10.3788/tfsr20240235

Vancouver

Chen Z, Liu Y, Gao H, Liang D, Wang Z, Zhang C, et al. Study on the pharmacokinetics of 2-fluorodeschloroketamine and its metabolite in rats. Forensic Sciences Research. 2026;11(1):tfsr20240235. doi:10.3788/tfsr20240235

BibTeX
@article{Chen2026,
  author = {Chen, Zhe and Liu, Ye and Gao, Huan and Liang, Di and Wang, Zhuoyi and Zhang, Chao and Li, Jianguo and Wei, Zhiwen and Zhang, Dan and Yun, Keming},
  title = {Study on the pharmacokinetics of 2-fluorodeschloroketamine and its metabolite in rats},
  journal = {Forensic Sciences Research},
  year = {2026},
  volume = {11},
  number = {1},
  pages = {tfsr20240235},
  doi = {10.3788/tfsr20240235}
}
Kostenlos starten →